Brodalumab is a human monoclonal antibody that binds to the interleukin-17 receptor and inhibits the binding of IL-17 to its receptor. Brodalumab has been approved for the treatment of moderate to severe plaque psoriasis.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.